CeeTox takes on former ADMETRx asset


In vivo toxicity prediction specialist to expand its range of in vitro service offerings

In vivo toxicity prediction specialist CeeTox has announced the completion of the purchase of certain assets formerly owned by ADMETRx. The deal will allow CeeTox to increase its existing ADME capabilities, as well as expanding its range of in vitro service offerings, according to the company.

Under the new agreement, former ADMETRx founder, ceo and chief scientific officer, Dr Phil Burton joins CeeTox as director, ADME services, along with a number of ADMETRx scientists.

“We are pleased to have Phil on board as we continue to build a powerful CRO specialised in delivering all of the in vitro capabilities required by regulation or standard practice,” commented CeeTox president, Tim Michell. “We are designing our company with a single minded focus – to serve the needs of our clients with outstanding science, service, flexibility and availability.”